Xtl Biopharmaceuticals (XTLB) Capital Expenditures Growth (1y) (2012 - 2015)
Xtl Biopharmaceuticals (XTLB) Capital Expenditures Growth (1y) (2012 - 2015) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | - |
| 4 | BeOne Medicines | 471.51 Bn | 466.72 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.70 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 143.40% |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 100.00% |
| Jun 30, 2015 | 50.00% |
| Dec 31, 2014 | 102.70% |
| Jun 30, 2014 | -100.00% |
| Mar 31, 2014 | 25.00% |
| Dec 31, 2013 | -1,750.00% |
| Mar 31, 2013 | -700.00% |
| Dec 31, 2012 | -300.00% |
| Mar 31, 2012 | 88.89% |